Welcome to our dedicated page for Adial Pharmaceuticals news (Ticker: ADIL), a resource for investors and traders seeking the latest updates and insights on Adial Pharmaceuticals stock.
Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) is a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addictions and related disorders. News about Adial often centers on the progress of its lead investigational drug, AD04, a genetically targeted serotonin-3 receptor antagonist being developed for Alcohol Use Disorder (AUD) in heavy drinking patients with specific genotypes.
On this page, readers can find coverage of Adial’s clinical development milestones, including updates on the ONWARD™ pivotal Phase 3 trial and preparations for a new Phase 3 adaptive program informed by End of Phase 2 (EOP2) feedback from the U.S. Food and Drug Administration (FDA). Company announcements describe FDA recognition of AUD as an unmet need, support for Adial’s adaptive trial design, and confirmation of primary efficacy endpoints based on heavy drinking days.
Adial’s news flow also highlights its precision medicine strategy. Releases describe a partnership with Genomind to validate a cheek swab genetic test that identifies SNPs in serotonergic system genes such as HTR3A, HTR3B, and SLC6A4, enabling selection of biomarker-positive patients, including those with the AG+ genotype. Additional stories cover intellectual property developments, such as provisional and international patent applications for AD04 that the company expects, once granted, to protect core assets to at least 2045.
Investors and observers can also follow capital markets and listing-related updates, including public offerings of stock and warrants, at-the-market sales agreements, Nasdaq compliance notices, and extensions related to minimum bid price requirements. Together, these items provide context on how Adial is financing and structuring its efforts to advance AD04 and its broader addiction treatment pipeline. Bookmark this page to review new regulatory, clinical, financing, and intellectual property announcements as they are reported.
Adial Pharmaceuticals (NASDAQ: ADIL) praised bipartisan H.R. 7091, the Expanding Veterans’ Access to Emerging Treatments Act, introduced March 24, 2026 to expand R&D access for veteran health conditions including Alcohol Use Disorder (AUD).
The bill recognizes non‑abstinence recovery outcomes and could support investigational therapies like Adial’s genetically targeted candidate AD04, which targets reductions in heavy drinking days as a clinical endpoint.
Adial Pharmaceuticals (NASDAQ: ADIL) reported 2025 fiscal results and a business update on March 6, 2026. Key achievements include positive AD04-103 PK results, productive End-of-Phase 2 engagement and supportive FDA feedback on an in vitro bridging strategy, expanded IP with a PCT filing extending protection through at least 2045, secured U.S. manufacturing partnerships, and strategic development partnerships for Phase 3 planning.
Financials: cash of $5.9M at year-end, R&D down 19%, and net loss improved to $8.0M for 2025; cash runway expected into H2 2026.
Adial Pharmaceuticals (NASDAQ: ADIL) entered an exclusive collaboration framework with Molteni Farmaceutici on March 3, 2026, to pursue European commercialization of AD04. The framework anticipates nearly $60 million in potential milestones and royalties, subject to a definitive agreement and AD04 progressing through clinical development.
The pact grants Molteni exclusivity to evaluate feasibility and sets terms for upfront, milestone, and tiered royalties (high single to low double digits). Adial cites genotype-driven Phase 3 design, manufacturing arrangements, a patent filing extending LOE to 2045 if granted, and simplified cheek-swab genetic screening.
Adial Pharmaceuticals (NASDAQ: ADIL) regained compliance with Nasdaq Listing Rule 5550(a)(2) after the company's common stock traded with a closing bid of at least $1.00 for 10 consecutive business days from Feb 6–20, 2026. Nasdaq notified the company on Feb 23, 2026 that the matter is closed.
The company said it is advancing AD04 toward a pivotal Phase 3 program, described improvements in clinical strategy, regulatory alignment, and manufacturing readiness, and disclosed ongoing advanced strategic partnering discussions to support next‑phase development and commercialization.
Adial Pharmaceuticals (NASDAQ: ADIL) highlighted recent FDA policy direction that may permit drug approval based on one adequate and well-controlled clinical investigation plus confirmatory evidence rather than two independent pivotal trials, where scientifically justified. This could lower Phase 3 costs, improve capital efficiency, and accelerate an NDA pathway for AD04.
The company plans to engage with the FDA on an appropriate evidentiary strategy for AD04, a genetically targeted serotonin-3 receptor antagonist for Alcohol Use Disorder.
Adial Pharmaceuticals (NASDAQ: ADIL) announced CEO Cary Claiborne will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on Wednesday, February 25, 2026 at 2:40 p.m. ET. The presentation will be webcast live and available for replay.
Adial management will also hold one‑on‑one meetings with approved investors during the virtual conference, held February 25–26, 2026.
Adial (NASDAQ: ADIL) applauded the Feb. 4, 2026 federal appropriations bill that includes a Congressional directive titled “Alternative Clinical Trial Endpoints for Substance Use Disorders.” The law directs the FDA and NIDA to collaborate on non‑abstinence endpoints—such as reduced cravings or disorder severity—that demonstrate meaningful clinical benefit.
Adial says the directive aligns with NIAAA’s updated recovery definition and could strengthen the regulatory pathway for its lead investigational therapy, AD04, which targets Alcohol Use Disorder using a precision medicine approach.
Adial Pharmaceuticals (NASDAQ: ADIL) will effect a 1-for-25 reverse stock split effective Feb 5, 2026 at 11:59 p.m. ET, reducing outstanding common shares from ~27.8 million to ~1.1 million and retaining the ADIL ticker. Common stock will trade on a split-adjusted basis on Feb 6, 2026.
The split is intended to restore compliance with Nasdaq's $1.00 minimum bid price, provide a new CUSIP 00688A304, adjust outstanding equity awards and warrants proportionally, and cash out fractional shares based on the 10-day average closing price preceding effectiveness.
Adial (NASDAQ: ADIL) announced publication of an international PCT patent application for AD04 on January 14, 2026. AD04 is described as the company’s lead investigational genetically targeted serotonin-3 receptor antagonist for treating Alcohol Use Disorder (AUD) in heavy drinking patients (defined in the release as < 10 drinks/drinking day). The company said the patent, if granted, is expected to protect Adial’s core assets through at least 2045. Management attributed the application to an extensive examination of clinical data after hiring new patent counsel and said the filing was originally made in July 2024.
Adial Pharmaceuticals (NASDAQ: ADIL) announced a warrant inducement agreement with an existing healthcare institutional investor to support immediate exercise of existing Series C-1 and Series E warrants at a reduced exercise price of $0.31. The exercises could purchase up to 9,215,675 shares of common stock and generate approximately $2.86 million in gross proceeds before fees and expenses.
In a private placement, the investor will receive new unregistered Series F warrants to purchase up to 13,823,512 shares at $0.31, exercisable after shareholder approval and expiring 24 months after the Approval Date. Closing is expected on or about December 1, 2025, subject to customary conditions.